Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyka LabsBOM:500259 +1.97%51 Return-on-Tangible-Asset is 4.92% as of Jun. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 51/100 and a GF Value™ of ₹129.44 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Lyka Labs ranks better than 74.4% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lyka Labs's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹83 Mil. Lyka Labs's average total tangible assets for the quarter that ended in Jun. 2026 was ₹1,678 Mil. Therefore, Lyka Labs's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 4.92%.
The historical rank and industry rank for Lyka Labs's Return-on-Tangible-Asset or its related term are showing as below:
BOM:500259'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -37.23 Med: -4.59 Max: 25.22
Current: -5.4
During the past 13 years, Lyka Labs's highest Return-on-Tangible-Asset was 25.22%. The lowest was -37.23%. And the median was -4.59%.
BOM:500259's Return-on-Tangible-Asset is ranked better than 74.4% of 1414
companies
in the Biotechnology industry
Industry Median: -35.985
vs BOM:500259: -5.40
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Lyka Labs Return-on-Tangible-Asset Related Terms
Lyka Labs Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Lyka Labs's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.92% mean?
Lyka Labs (BOM:500259) has a Return-on-Tangible-Asset of 4.92% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #362 out of 1414 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Lyka Labs' Return-on-Tangible-Asset too high?
Lyka Labs' current Return-on-Tangible-Asset is 4.92%. Based on the distribution chart, Lyka Labs ranks #362 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #362 out of 1414 companies for Return-on-Tangible-Asset. This puts Lyka Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lyka Labs and its competitors. Lyka Labs's current Return-on-Tangible-Asset is 4.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹129.44, compared to a current price of ₹74.45 — trading 42.5% below its estimated fair value. The current Return-on-Tangible-Asset is 4.92%. Lyka Labs' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Return-on-Tangible-Asset is 4.92% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹74.45 is trading 42.5% below its estimated GF Value™ of ₹129.44.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Return-on-Tangible-Asset: 4.92%
GF Value™: ₹129.44 vs. price of ₹74.45 (42.5% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score
Get the complete analysis for BOM:500259
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
